Pediatric Infectious Disease

Register      Login

VOLUME 4 , ISSUE 3 ( July-September, 2022 ) > List of Articles

Guest Editorial

Kawasaki Disease

Nameirakpam Johnson, Surjit Singh

Citation Information : Johnson N, Singh S. Kawasaki Disease. Pediatr Inf Dis 2022; 4 (3):00-00.

DOI: 10.5005/pid-4-3-iv

License: CC BY-NC 4.0

Published Online: 31-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

PDF Share
  1. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17). doi:10.1161/CIR.0000000000000484
  2. Singh S, Aulakh R, Bhalla AK, et al. Is Kawasaki disease incidence rising in Chandigarh, North India? Arch Dis Child. 2011;96(2):137-140. doi:10.1136/adc.2010.194001
  3. Suzuki A, Kamiya T, Kuwahara N, et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol. 1986;7(1):3-9. doi:10.1007/BF02315475
  4. Kawasaki T. [Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children]. Arerugi Allergy. 1967;16(3):178-222.
  5. Makino N, Nakamura Y, Yashiro M, et al. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatr Int Off J Jpn Pediatr Soc. 2019;61(4):397-403. doi:10.1111/ped.13809
  6. Cimaz R, Fanti E, Mauro A, et al. Epidemiology of Kawasaki disease in Italy: surveillance from national hospitalization records. Eur J Pediatr. 2017;176(8):1061-1065. doi:10.1007/s00431-017-2947-3
  7. Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child. 2015;100(11):1084-1088. doi:10.1136/archdischild-2014-307536
  8. Jindal AK, Pilania RK, Guleria S, et al. Kawasaki Disease in Children Older Than 10 Years: A clinical experience from northwest India. Front Pediatr. 2020;8:24. doi:10.3389/fped.2020.00024
  9. Xie X, Shi X, Liu M. The roles of genetic factors in Kawasaki disease: A systematic review and meta-analysis of genetic association studies. Pediatr Cardiol. 2018;39(2):207-225. doi:10.1007/s00246-017-1760-0
  10. Onouchi Y, Fukazawa R, Yamamura K, et al. Variations in ORAI1 gene associated with Kawasaki disease. Xu S-Z, ed. PLOS ONE. 2016;11(1):e0145486. doi:10.1371/journal.pone.0145486
  11. Nagata S. Causes of Kawasaki disease-from past to present. Front Pediatr. 2019;7:18. doi:10.3389/fped.2019.00018
  12. Rodó X, Curcoll R, Robinson M, et al. Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci U S A. 2014;111(22):7952-7957. doi:10.1073/pnas.1400380111
  13. Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat Rev Rheumatol. 2020;16(7):391-405. doi:10.1038/s41584-020-0426-0
  14. Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009;123(5):e783-789. doi:10.1542/peds.2008-1871
  15. Dionne A, Dahdah N. Myocarditis and Kawasaki disease. Int J Rheum Dis. 2018;21(1):45-49. doi:10.1111/1756-185X.13219
  16. García-Pavón S, Yamazaki-Nakashimada MA, Báez M, et al. Kawasaki disease complicated with macrophage activation syndrome: A systematic Review. J Pediatr Hematol Oncol. 2017;39(6):445-451. doi:10.1097/MPH.0000000000000872
  17. Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis. 2020;79(8):999-1006. doi:10.1136/annrheumdis-2020-217960
  18. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet Lond Engl. 2020;395(10239):1771-1778. doi:10.1016/S0140-6736(20)31103-X
  19. Singhal M, Gupta P, Singh S, Khandelwal N. Computed tomography coronary angiography is the way forward for evaluation of children with Kawasaki disease. Glob Cardiol Sci Pract. 2018;2017(3). doi:10.21542/gcsp.2017.28
  20. Zheng X, Yue P, Liu L, et al. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a meta-analysis. PloS One. 2019;14(5):e0217274. doi:10.1371/journal.pone.0217274
  21. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606-2612. doi:10.1161/CIRCULATIONAHA.105.592865
  22. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237-240. doi:10.1016/j.jpeds.2006.03.050
  23. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131-137. doi:10.1007/s00431-006-0223-z
  24. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831-835.e3. doi:10.1016/j.jpeds.2010.10.031
  25. Zhu B-H, Lv H-T, Sun L, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr. 2012;171(3):571-578. doi:10.1007/s00431-011-1585-4
  26. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833-838. doi:10.1016/j.jpeds.2008.06.011
  27. Mori M, Hara T, Kikuchi M, et al. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep. 2018;8(1):1994. doi:10.1038/s41598-017-18387-7
  28. Miura M, Kobayashi T, Igarashi T, et al. Real-world safety and effectiveness of infliximab in pediatric patients with acute Kawasaki disease: A Postmarketing Surveillance in Japan (SAKURA Study). Pediatr Infect Dis J. 2020;39(1):41-47. doi:10.1097/INF.0000000000002503
  29. Roberts SC, Jain S, Tremoulet AH, et al. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemp Clin Trials. 2019;79:98-103. doi:10.1016/j.cct.2019.02.008
  30. Portman MA, Dahdah NS, Slee A, et al. Etanercept With IVIg for acute Kawasaki disease: A randomized controlled trial. Pediatrics. 2019;143(6). doi:10.1542/peds.2018-3675
  31. Kone-Paut I, Cimaz R, Herberg J, et al. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series. Autoimmun Rev. 2018;17(8):768-774. doi:10.1016/j.autrev.2018.01.024
  32. Kone-Paut I, Tellier S, Belot A, et al. Open label, phase ii study with anakinra in intravenous immunoglobulin-resistant Kawasaki disease. Arthritis Rheumatol. Published online August 11, 2020:art.41481. doi:10.1002/art.41481
  33. Onouchi Y, Suzuki Y, Suzuki H, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J. 2013;13(1):52-59. doi:10.1038/tpj.2011.45
  34. Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet Lond Engl. 2019;393(10176):1128-1137. doi:10.1016/S0140-6736(18)32003-8
  35. Makino N, Nakamura Y, Yashiro M, et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015;25(3):239-245. doi:10.2188/jea.JE20140089
  36. Singh S, Bhattad S, Gupta A, et al. Mortality in children with Kawasaki disease: 20 years of experience from a tertiary care centre in North India. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S129-133.
  37. Maddox RA, Holman RC, Uehara R, et al. Recurrent Kawasaki disease: USA and Japan. Pediatr Int Off J Jpn Pediatr Soc. 2015;57(6):1116-1120. doi:10.1111/ped.12733
  38. Guleria S, Pilania RK, Jindal AK, et al. Recurrent Kawasaki disease at a tertiary care center in Chandigarh, North West India: 24 years of clinical experience. Int J Rheum Dis. 2019;22(7):1183-1187. doi:10.1111/1756-185X.13519
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.